» Articles » PMID: 36572864

Comparative Epigenomics by Machine Learning Approach for Neuroblastoma

Overview
Journal BMC Genomics
Publisher Biomed Central
Specialty Genetics
Date 2022 Dec 26
PMID 36572864
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuroblastoma (NB) is the second most common pediatric solid tumor. Because the number of genetic mutations found in tumors are small, even in some patients with unfavorable NB, epigenetic variation is expected to play an important role in NB progression. DNA methylation is a major epigenetic mechanism, and its relationship with NB prognosis has been a concern. One limitation with the analysis of variation in DNA methylation is the lack of a suitable analytical model. Therefore, in this study, we performed a random forest (RF) analysis of the DNA methylome data of NB from multiple databases.

Results: RF is a popular machine learning model owing to its simplicity, intuitiveness, and computational cost. RF analysis identified novel intermediate-risk patient groups with characteristic DNA methylation patterns within the low-risk group. Feature selection analysis based on probe annotation revealed that enhancer-annotated regions had strong predictive power, particularly for MYCN-amplified NBs. We developed a gene-based analytical model to identify candidate genes related to disease progression, such as PRDM8 and FAM13A-AS1. RF analysis revealed sufficient predictive power compared to other machine learning models.

Conclusions: RF is a useful tool for DNA methylome analysis in cancer epigenetic studies, and has potential to identify a novel cancer-related genes.

Citing Articles

Artificial Intelligence Applications in Oral Cancer and Oral Dysplasia.

Viet C, Zhang M, Dharmaraj N, Li G, Pearson A, Manon V Tissue Eng Part A. 2024; 30(19-20):640-651.

PMID: 39041628 PMC: 11564848. DOI: 10.1089/ten.TEA.2024.0096.


Integrating Omics Data and AI for Cancer Diagnosis and Prognosis.

Ozaki Y, Broughton P, Abdollahi H, Valafar H, Blenda A Cancers (Basel). 2024; 16(13).

PMID: 39001510 PMC: 11240413. DOI: 10.3390/cancers16132448.


Predicting Neuroblastoma Patient Risk Groups, Outcomes, and Treatment Response Using Machine Learning Methods: A Review.

Jahangiri L Med Sci (Basel). 2024; 12(1).

PMID: 38249081 PMC: 10801560. DOI: 10.3390/medsci12010005.

References
1.
Teitz T, Wei T, Valentine M, Vanin E, Grenet J, Valentine V . Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000; 6(5):529-35. DOI: 10.1038/75007. View

2.
Henrich K, Bender S, Saadati M, Dreidax D, Gartlgruber M, Shao C . Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. Cancer Res. 2016; 76(18):5523-37. DOI: 10.1158/0008-5472.CAN-15-2507. View

3.
Zhang L, Lv C, Jin Y, Cheng G, Fu Y, Yuan D . Deep Learning-Based Multi-Omics Data Integration Reveals Two Prognostic Subtypes in High-Risk Neuroblastoma. Front Genet. 2018; 9:477. PMC: 6201709. DOI: 10.3389/fgene.2018.00477. View

4.
Fardin P, Barla A, Mosci S, Rosasco L, Verri A, Varesio L . The l1-l2 regularization framework unmasks the hypoxia signature hidden in the transcriptome of a set of heterogeneous neuroblastoma cell lines. BMC Genomics. 2009; 10:474. PMC: 2768750. DOI: 10.1186/1471-2164-10-474. View

5.
Zheng C, Xu R . Predicting cancer origins with a DNA methylation-based deep neural network model. PLoS One. 2020; 15(5):e0226461. PMC: 7209244. DOI: 10.1371/journal.pone.0226461. View